Look up one drug

Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Act Celecoxib · DIN 02420163 Manufacturer: Actavis Pharma Company; listing date 2015-01-28 Health Canada: Cancelled post market since 2022-07-29 · brand ACT CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 200 MG · company Teva canada limited · schedule Prescription

DIN 02420163: Act Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804076; group id 377; item number 0899; lccId 00064; manufacturer id ACV Source form: Cap; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.2558; ministry $0.2558 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02420163 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90477 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.

Interchangeable products

AG-Celecoxib · DIN 02437589 · $0.2558 Apo-Celecoxib · DIN 02418940 · $0.2558 Auro-Celecoxib · DIN 02445689 · $0.2558 Bio-Celecoxib · DIN 02426390 · $0.2558 Celebrex · DIN 02239942 · $0.2558 Celecoxib · DIN 02429683 · $0.2558 Celecoxib · DIN 02436302 · $0.2558 Jamp-Celecoxib · DIN 02424541 · $0.2558 M-Celecoxib · DIN 02495473 · $0.2558 Mar-Celecoxib · DIN 02420066 · $0.2558 Mint-Celecoxib · DIN 02412500 · $0.2558 NRA-Celecoxib · DIN 02479745 · $0.2558 PMS-Celecoxib · DIN 02355450 · $0.2558 PMSC-Celecoxib · DIN 02517124 · $0.2558 Ran-Celecoxib · DIN 02412381 · $0.2558 Sdz Celecoxib · DIN 02442647 · $0.2558 Teva-Celecoxib · DIN 02288923 · $0.2558

Shortage status: active shortage (reported 2021-02-17, last updated 2021-05-06) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02420163

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2022-07-29 — choose a marketed DIN from the same-category list.